Virus-Safe Products: Pathogen Reduction and Inactivation

Blood Banking and Transfusion Medicine

Volumn , Issue , 2007, Pages 383-396

  Corash, Laurence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882460076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06981-9.50032-6     Document Type: Chapter

References (156)

1. Dodd RY Will blood products be free of infectious agents?. Transfusion Medicine in the 1990s 1990, 223-251. American Association of Blood Banks, Arlington, Va. S.J. Nance (Ed.).
2. Laperche S Blood safety and nucleic acid testing in Europe. Euro Sur-veill 2005, 10:3-4.
3. Alvarez do Barrio M, Gonzalez Diez R, Sanchez Hernandez JM, Oyon-arte Gomez S Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005, 10:20-22.
4. Offergeld R, Faensen D, Ritter D, Hamouda O Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany, 2000-2002: risk of virus transmission and the impact of nucleic acid testing. Euro Surveill 2005, 10:8-11.
5. Busch MP, Kleinman SH, Nemo GJ Current and emerging infectious risks of blood transfusions. JAMA 2003, 289:959-962.
6. Satake M Lookback study for transfusion-related HBV infection in Japan. Transfusion 2005, 45(Suppl 3):9A-10A.
7. McQuiston JH, Childs JE, Chamberland ME, Tabor E Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000, 40:274-284.
8. Schmunis GA Trypanosoma cruzi, the etiologic agent of Chagas disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991, 31:547-557.
9. Grant IH, Gold JM, Wittner M, et al. Transfusion-associated acute Cha-gas disease acquired in the United States. Ann Intern Med 1989, 111:849-851.
10. Nickerson P, Orr P, Schroeder ML, Sekla L, Johnston JB Transfusion-associated Trypanosoma cruzi infection in a nonendemic area. Ann Intern Med 1989, 111:851-853.
11. Riera C, Muncunill J, Fisa R, et al. Asymptomatic infection by Leishma-nia infantum in blood donors from the Balearic Islands, Spain. Transfusion 2005, 45(Suppl 3):18A.
12. Leiby DA, Gill JE Transfusion-transmitted tick-borne infections: a cornucopia of threats. Transfus Med Rev 2004, 18:293-306.
13. Linden JV, Wong SJ, Chu FK, Schmidt GB, Bianco C Transfusion-associated transmission of babesiosis in New York State. Transfusion 2000, 40:285-289.
14. Petersen LR, Epstein JS Problem solved? West Nile virus and transfusion safety. N Engl J Med 2005, 353:516-517.
15. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003, 101:2196-2203.
16. Busch MP, Cagliotti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005, 353:460-467.
17. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005, 353:451-459.
18. Fiebig EW, Hildebrant CM, Smith RI, Conras EA, Vos MC, Vermeij H, van Rhenen DJ Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005, 45:514-519.
19. Visconti MR, Pennington J, Garner SF, Allain JP, Williamson LM Assessment of removal of human cytomegalovirus from blood components by leucocyte depletion filters using real-time quantitative PCR. Blood 2004, 103:1137-1139.
20. Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002, 100:677-681.
21. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101:4195-4200.
22. Blajchman MA Bacterial contamination of cellular components: risks, sources, and control. Vox Sang 2004, 87(Suppl 1):S98-S103.
23. Te Boekhorst PA, Beckers EA, Vos MC, Vermeij H, van Rhenen DJ Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 2005, 45:514-519.
24. Munksgaard L, Albjerg L, Lillevang ST, Gahrn-Hansen B, Georgsen J Detection of bacterial contamination of platelet components: six years' experience with the BactT/ALERT system. Transfusion 2004, 44:1166-1173.
25. Claeys H, Logghe F, Vandekerchove B, et al. Four-year experience with routine bacterial screening of platelet concentrates. Transfus Med 2003, 1(Suppl 1):S326.
26. Larsen CP, Ezligini F, Hermansen NO, Kjeldsen-Kragh J Six years' experience of using the BactT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005, 88:93-97.
27. Sapatnekar S, Wood EM, Miller JP, et al. Methicillin-resistant Staphy-lococcus aureus sepsis associated with the transfusion of contaminated platelets: a case report. Transfusion 2001, 41:1426-1430.
28. Chiu EK, Yuen KY, Lie AK, et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994, 34:950-954.
29. Sullivan MT, McCullough J, Schreiber GB, Wallace EL Blood collection and transfusion in the United States in 1997. Transfusion 2002, 42:1253-1260.
30. Srinivasan A. Septic transfusion reactions despite implementation of methods to reduce bacterial contamination. Paper presented at the Advisory Committee on Blood Safety and Availability, Bethesda, Md., 2005.
31. Laperche S, Pillonel J Residual risk of transfusion-transmitted HIV, HCV, and HBV infections in France and impact of NAT. Vox Sang 2004, 87(Suppl 3):S23.
32. Blajchman MA, Beckers EA, Dickmeiss E, Lin L, Moore G, Muylle L Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005, 19:259-272.
33. Benjamin RJ Bacterial detection in platelet components and the rationale for pathogen inactivation: a blood center perspective. J Clin Apher 2005, 20:117-122.
34. Horowitz B, Wiebe ME, Lippin A, Stryker MH Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985, 25:516-522.
35. Heddle NM, Kalma L, Singer J, et al. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994, 331:625-628.
36. Ohto H, Anderson KC Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996, 10:31-43.
37. Lee TH, Parlieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005, 45:1280-1290.
38. Ben-Hur E, Moor ACE, Margolis-Nunno H, et al. The photodecontami-nation of cellular blood components: mechanisms and use of photosen-sitization in transfusion medicine. Transfus Med Rev 1996, 10:15-22.
39. Wollowitz S Targeting DNA and RNA in pathogens: mode of action of amotoslaen HCl. Transfus Med Hemother 2004, 31(Suppl 1):11-16.
40. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004, 80:15-21.
41. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and UVA inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004, 44:1496-1504.
42. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Depuis K Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003, 47:475-479.
43. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005, 45:1459-1463.
44. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005, 45:580-590.
45. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998, 91:2180-2188.
46. Lin L, Wiesehahn GP, Morel PA, Corash L Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood 1989, 74:517-525.
47. Alter HJ, Morel PA, Dorman BP, et al. Photochemical decontamination of blood components containing hepatitis B and non-A, non-B virus. Lancet 1988, 2:1446-1450.
48. Goodrich RP, Yerram NR, Tay GB, et al. Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives. Proc Natl Acad Sci USA 1994, 91:5552-5556.
49. Goodrich RP, Yerram NR, Crandall SL, Sowemimo-Coker SO In vivo survival of platelets subjected to virus inactivation protocols using pso-ralen and coumarin photosensitizers. Blood 1995, 86(Suppl 1):354A.
50. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004, 44:1159-1165.
51. Hei DJ, Grass J, Lin L, Corash L, Cimino G Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999, 39:239-248.
52. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999, 93:3140-3147.
53. Bruchmiller I, Janetzko K, Bugert P, et al. Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Transfusion 2005, 45:1464-1472.
54. Van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000, 79:206-214.
55. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard L, Goodrich RP Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004, 44:877-885.
56. Goodrich RP The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000, 78(Suppl 2):211-215.
57. Lippert L, Watson R, Doane S, Reddy H, Goodrich R Inactivation of Plasmodium falciparum by riboflavin and light. Vox Sang 2002, 83(Suppl 2):163.
58. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005, 45:911-919.
59. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004, 87:82-90.
60. Fast LD, DiLeone GR, Li J, Goodrich RP Mirasol PRT treatment of human white blood cells prevents the development of xenogeneic graft versus host disease. Transfusion 2005, 45(3 Suppl):28A-29A.
61. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004, 104:1534-1541.
62. Van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
63. Snyder E, Raife T, Lin L, et al. Recovery and lifespan of 111 indium-radio-labeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004, 44:1732-1740.
64. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005, 45:1864-1875.
65. Osselaer JC, Doyen C, Sonet A, et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and costs. Blood 2004, 104:3629.
66. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in thrombocytopenic patients. Transfusion 2005, 45:1864-1875.
67. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
68. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
69. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia. N Engl J Med 1997, 337:1870-1875.
70. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P Methodological issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003, 43:742-752.
71. Corash L How much do we know about the platelet transfusion threshold?. Transfusion 2003, 43:691-693.
72. Heddle NM, Cook RJ, Rebulla P, Slichter SJ, Sigouin C, Murphy MF Bleeding in patients with acute leukemia. Vox Sang 2002, 83(Suppl 2):8.
73. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005, 105:4106-4114.
74. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of throm-bocytopenia: an analysis of the SPRINT trial of platelets photochemi-cally treated with amotosalen HCl and ultraviolet A light. Transfusion 2006, 46:24-33.
75. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
76. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005, 45:1864-1875.
77. Lin L, Conlan MG, Tessman J, Cimino G, Porter S Amotosalen interactions with platelet and plasma components: absence of neoanti-gen formation after photochemical treatment. Transfusion 2005, 45:1610-1620.
78. Osselaer JC, Bueno JL, Messe N, Jacquet M, Castro E, Flament J Prospective active hemovigilance plan for INTERCEPT platelets in Europe: a status report. Vox Sang 2005, 89:137.
79. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
80. Rywkin S, Ben-Hur E, Reid ME, Oyen R, Ralph H, Horowitz B Selective protection against IgG binding to red cells treated with phthalocyanines and red light for virus inactivation. Transfusion 1995, 35:414-420.
81. Ben-Hur E, Rywkin S, Rosenthal I, Geacintov NE, Horowitz B Virus inactivation in red cell concentrates by photosensitization with phthalo-cyanines: protection of red cells but not of vesicular stomatitis virus with a water-soluble analogue of vitamin E. Transfusion 1995, 35:401-406.
82. Wagner SJ, Skirpchenko A, Robinette D, Mallory DA, Cincotta L Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue. Transfusion 1998, 38:729-737.
83. Besselink GA, van Engelenburg FA, Korsten HG, et al. The band III ligand dipyridamole protects human RBCs during photodynamic treatment while extracellular virus inactivation is not affected. Transfusion 2002, 42:728-733.
84. Wagner SJ, Skripchenko A, Cincotta L, Thompson-Montgomery D, Awatefe H Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties. Transfusion 2005, 45:752-760.
85. Fast LD, DiLeone G, Edson CM, Purmal A PEN 110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002, 42:1318-1325.
86. Jayarama V, Lazo A, Marcello J, et al. Inactine PEN 110 inactivates cell-free and cell-associated CMV in red cell concentrates. Transfusion 2003, 43(Suppl 9):8A.
87. Ohagen A, Gibaja V, Aytay S, Horrigan J, Lunderville D, Lazo A Inacti-vation of HIV in blood. Transfusion 2002, 42:1308-1317.
88. Edson CM, Purmal A, Brown F, Valeri CR, Budowsky E, Chapman JR Viral inactivation of red blood cell concentrates by Inactine: mechanism of action and lack of effect on red cell physiology. Transfusion 1999, 39(Suppl 1):108S.
89. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated red cell concentrates using PEN 110 chemistry: a phase I clinical study. Transfusion 2002, 42:146-152.
90. Snyder E, Mintz P, Burks S, et al. Pathogen inactivated red blood cells using Inactine technology demonstrate 24-hour posttransfusion recovery equal to untreated red cells after 42 days of storage. Blood 2001, 98(Suppl 1):109A.
91. Cook D, Stassinopoulos A, Merritt J, et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303. Blood 1997, 90(Suppl 1):409A.
92. Cook D, Stassinopoulos A, Wollowitz S, et al. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood 1998, 92(Suppl 1):503A.
93. Ciaravino V, McCullough T, Woods N, Sullivan T Absence of carci-nogenicity in a 26-week intravenous study with S-303-treated mouse red blood cells in C57BL/6TAC-TRP53TML heterozygote mice. Blood Bank Transfus Med 2003, 1(Suppl 1):S365.
94. Greenwalt TJ, Hambleton J, Wages D, et al. Viability of red blood cells treated with a novel pathogen inactivation system. Transfusion 1999, 39(Suppl 1):109S.
95. Hambleton J, Greenwalt T, Viele M, et al. Posttransfusion recovery after multiple exposures to red blood cell concentrates (RBCS) treated with a novel pathogen inactivation (PI) process. Blood 1999, 94(Suppl 1):376A.
96. Wages D, Hambleton J, Viele M, et al. RBCs treated with Helinx pathogen inactivation have recovery and half-life comparable to conventional RBCS in a randomized crossover trial. Hematol J 2002, 3(Suppl 1):171.
97. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005, 45:1739-1749.
98. Conlan MG, Vichinsky E, Snyder E, et al. S-303 pathogen inactivated red blood cells in patients with hemoglobinopathies participating in chronic RBC programs: preliminary safety and efficacy results. Vox Sang 2005, 89(Suppl 1):121.
99. Conlan MG, Lin J, Stassinopoulos A Investigation of immunoreac-tivity observed after transfusion of S-303 RBCs in 2 phase III clinical trials in support of acute or chronic anemia. Transfusion 2005, 45(Suppl 3):29A.
100. Arndt PA, Garratty G A retrospective analysis of the value of mono-cyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004, 44:1273-1281.
101. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW Solvent/detergent treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992, 79:826-831.
102. Roberts P Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals 2000, 28:29-32.
103. Luban NL Human parvovirus: implications for transfusion medicine. Transfusion 1994, 34:821-827.
104. Horowitz MS, Pehta JC SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998, 74(Suppl 1):231-235.
105. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh frozen plasma on haemostasis and fibrinoly-sis in complex coagulopathy following open-heart surgery. Vox Sang 2002, 82:9-14.
106. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999, 39:1227-1234.
107. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang 1998, 74(Suppl 1):237-239.
108. Beeck H, Hellstern O In vitro characterization of solvent/detergent-treated human plasma and quarantine fresh frozen plasma. Vox Sang 1998, 74(Suppl 1):219-223.
109. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplas-min activity. Blood 1999, 94:3922-3927.
110. Beach KJ. Reported Serious Adverse Events in Liver Transplant Patients. V.I. Technologies Inc. Available at. Accessed March 28, 2006. http://www.fda.gov/med-watch/safety/2000/plassd.pdf.
111. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ Venous thromboembolism associated with management of acute throm-botic thrombocytopenic purpura. Br J Haematol 2003, 121:778-785.
112. Flamholz R, Jeon HR, Baron JM, Baron BW Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/ detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thrombosis?. J Clin Apher 2000, 15:169-172.
113. Mohr H, Lambrecht B, Knueyer-Hopf J Virus inactivated single-donor fresh plasma preparations. Infusionsther Transfusionsmed 1992, 19:79-83.
114. Garwood M, Cardigan RA, Drummond O, et al. The effect of methy-lene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003, 43:1238-1247.
115. Aznar JA, Bonanad S, Montoro JM, et al. Influence of methylene blue pho-toinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates, and cryosupernatants. Vox Sang 2000, 79:156-160.
116. Simonsen AC, Sorensen H Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy volunteers. Vox Sang 1999, 77:210-217.
117. Williamson LM, Cardigan R, Prowse CV Methylene blue-treated fresh-frozen plasma: what is the contribution to blood safety?. Transfusion 2003, 43:1322-1329.
118. Wieding JU, Rathberger J, Zenjer D Prospective, randomized trial and controlled study on solvent detergent versus methylene blue virus inactivated plasma. Transfusion 1999, 39:23S.
119. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-pho-toinactivated plasma vs fresh frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004, 86:246-251.
120. de la Rubria J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001, 114:721-723.
121. Atance R, Pereira A, Ramirez B Transfusing methylene blue-photoin-activated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001, 41:1548-1552.
122. Alfonso R, Lin C, Dupuis K, et al. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood 1996, 88(Suppl 1):526A.
123. Singh Y, Sawyer L, Pinkoski L, et al. Photochemical treatment of plasma with amotosalen and UVA light inactivates pathogens while retaining coagulation function. Transfusion 2006, 46:1168-1177.
124. Hervig T, Cazenave JP, Schlenke P, et al. INTERCEPT plasma: process validation studies in three European blood centers. Hematologica 2005, 90:246.
125. Wages D, Smith D, Walsh J, et al. Transfusion of therapeutic doses of virally inactivated fresh frozen plasma in healthy subjects. Blood 1997, 90(Suppl 1):409A.
126. Wages D, Radu-Radurescu L, Adams M, et al. Quantitative analysis of coagulation factors in response to transfusion of S-59 photochemi-cally treated fresh frozen plasma (S-59 FFP) and standard FFP. Blood 1998, 92(Suppl 1):503A.
127. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002, 42:1302-1307.
128. Wages D, Bass N, Keefe E, et al. Treatment of acquired coagulopathy by transfusion of fresh frozen plasma (FFP) prepared using a novel, single unit photochemical. Blood 1999, 94(Suppl 1):247A.
129. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inac-tivation (PCT-FFP): transfusion of patients with congenital factor deficiencies. Transfusion 2005, 45:1362-1372.
130. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006, 107:3753-3760.
131. Mintz PD, Neff A, MacKenzie M, et al. Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT plasma). Blood 2004, 104:239A.
132. Londe H, Damonte P, Corash L, Lin L Inactivation of human cyto-megalovirus with psoralen and UVA in human platelet concentrates. Blood 1995, 86(Suppl 1):544A.
133. Lin L, Londe H, Hanson CV, et al. Photochemical inactivation of cell-associated human immunodeficiency virus in platelet concentrates. Blood 1993, 82:292-297.
134. Eble BE, Corash L Photochemical inactivation of duck hepatitis B virus in human platelet concentrates: a model of surrogate human hepatitis B virus infectivity. Transfusion 1996, 36:406-418.
135. Lin L, Londe H, Janda JM, et al. Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood 1994, 83:2698-2706.
136. Dodd RY, Moroff G, Wagner S, et al. Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen-ultraviolet A and merocyanine 540-visible light methods. Transfusion 1991, 31:483-490.
137. Margolis-Nunno H, Williams B, Rywkin S, Geacintov N, Horowitz B Virus sterilization in platelet concentrates with psoralen and ultraviolet A light in the presence of quenchers. Transfusion 1992, 32:541-547.
138. Benade LE, Shumaker J, Xu Y, Chen X, Dodd RY Inactivation of free and cell-associated human immunodeficiency virus in platelet suspensions by aminomethyltrimethylpsoralen and ultraviolet light. Transfusion 1994, 34:680-684.
139. Margolis-Nunno M, Williams B, Rywkin S, Horowitz B Photochemical virus sterilization in platelet concentrates with psoralen derivatives. Thromb Haemost 1991, 65:1162.
140. Yerram N, Forster P, Goodrich T, et al. Comparison of virucidal properties of brominated psoralen with 8-methoxy psoralen (8-MOP) and aminomethyl trimethyl psoralen (AMT) in platelet concentrates. Blood 1993, 82(Suppl 1):402A.
141. Rai S, Kasturi C, Grayzar J, et al. Dramatic improvements in viral inac-tivation with brominated psoralens, napthalenes, and anthracenes. Photochem Photobiol 1993, 58:59-65.
142. Prodouz KN, Fratantoni JC, Boone EJ, Bonner RF Use of laser-UV for inactivation of virus in blood products. Blood 1987, 70:589-592.
143. Prodouz KN, Lytle CD, Keville EA, Budacz AP, Vargo S, Fratantoni JC Inhibition by albumin of merocyanine 540-mediated photosensitization of platelets and viruses. Transfusion 1991, 31:415-422.
144. Klein-Struckmeier A, Mohr H Virus inactivation by methylene blue light in thrombocyte concentrates. Vox Sang 1994, 67(Suppl 2):36.
145. Horowitz B, Rywkin S, Margolis-Nunno H, et al. Inactivation of viruses in red cell and platelet concentrates with aluminum phthalocyanine (AlPc) sulfonates. Blood Cells 1992, 18:141-150.
146. Matthews JL, Sogandres-Bernal F, Judy M, et al. Inactivation of viruses with photoactive compounds. Blood Cells 1992, 18:75-89.
147. North J, Neyndorff H, King D, Levy JG Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative. Blood Cells 1992, 18:129-140.
148. Sieber F, Krueger GJ, O'Brien JM, Schober SL, Sensenbrenner LL, Sharkis SJ Inactivation of friend erythroleukemia virus and friend virus-transformed cells by merocyanine 540-mediated photosensitization. Blood 1989, 73:345-350.
149. O'Brien JM, Gaffney DK, Wang TP, Sieber F Merocyanine 540-sensi-tized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. Blood 1992, 80:277-285.
150. Smith OM, Dolan SA, Dvorak JA, Wellems TE, Sieber F Merocyanine 540-sensitized photoinactivation of human erythrocytes parasitized by Plasmodium falciparum. Blood 1992, 80:21-24.
151. Wagner SJ, Storry JR, Mallory DA, Stromberg RR, Benade LE, Friedman LI Red cell alterations associated with virucidal methylene blue phototreatment. Transfusion 1993, 33:30-36.
152. Wagner SJ, Robinette D, Storry J, Chen XY, Shumaker J, Benade L Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion 1994, 34:521-526.
153. Horowitz B, Williams B, Rywkin S, et al. Inactivation of viruses in blood with aluminum phthalocyanine derivatives. Transfusion 1991, 31:102-108.
154. Yerram N, Platz MS, Forster P, Goodrich T, Goodrich R Selective viral inactivation in RBC, platelets, and plasma using a novel psoralen derivative plus ultraviolet A (UVA) light. Transfusion 1993, 33(Suppl 9):50S.
155. Lavie G, Mazur Y, Lavie D, et al. Hypericin as an inactivator of infectious viruses in blood components. Transfusion 1995, 35:392-400.
156. Zhang QX, Edson C, Budowsky E, Purmal A Inactine: a method for viral inactivation in red blood cell concentrates. Transfusion 1998, 38(Suppl 10):75S.